Sage shares surge as depression drug succeeds mid-stage trial

(Reuters) – Sage Therapeutics Inc’s shares surged more than 63 percent premarket on Thursday, on track to add about $2.5 billion to the company’s market value, after its drug succeeded in reducing the symptoms of depression in a mid-stage trial.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply